3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Sezary Syndrome
1
Sarcoma, Synovial
1
Recurrence
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Lymphoma
1
Liposarcoma, Myxoid
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Hodgkin Disease
1
HIV Infections
1
Graft vs Host Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Brain Neoplasms
1
Acquired Immunodeficiency Syndrome
1
Interventions
Temozolomide
88
Bevacizumab
49
Radiotherapy
36
Irinotecan
22
Magnetic Resonance Spectroscopy
21
Surgical Procedures, Operative
17
Carboplatin
17
Carmustine
15
Radiation
13
Nivolumab
11
IL13-PE38
8
Erlotinib Hydrochloride
8
Thalidomide
7
Radiotherapy, Intensity-Modulated
7
Lomustine
7
Imatinib Mesylate
7
Everolimus
7
Aminolevulinic Acid
7
sargramostim
6
Topotecan
6
O(6)-benzylguanine
6
Cyclophosphamide
6
Chemotherapy, Adjuvant
6
vandetanib
5
temsirolimus
5
fluorodopa F 18
5
Vincristine
5
Surveys and Questionnaires
5
Radiosurgery
5
Flucytosine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Glioma
×
interferon gamma-1b
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled